NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...

California VC firm Aditum Bio is reaching across the Pacific to hatch a brand-new biotech. Teaming up with China-based Leads ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

In August, Trevena underwent a reverse stock split, a move often enacted when a company’s share price dips too low. The split wasn’t enough to stave off delisting, with Nasdaq removing Trevena’s stock ...

Sarepta Therapeutics has ended development of a late-phase Duchenne muscular dystrophy (DMD) drug candidate over a safety problem. The safety signal deprived Sarepta of a near-term shot at accelerated ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

Celldex Therapeutics has halted work on its solid-tumor-focused bispecific as the biotech prioritizes its work in ...

The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...

When tested in mice, the compound—named BBI-2779—shrank gastric tumors and prevented the cancer from developing resistance to ...